FDA Requirements for Korean Skincare in 2026: MoCRA, Labeling, and Import Basics

Regulatory status last reviewed: September 4, 2026. Requirements depend on the product, its claims and intended use, the parties involved, and whether a statutory exemption applies. This article provides general information and is not legal or regulatory advice.

Regulatory status last reviewed: September 8, 2026.

By Liz Song, founder of ALTA MEET

Quick Answer

Most cosmetics do not require FDA premarket approval. Under MoCRA (effective since December 2023), U.S. cosmetic requirements center on facility registration, product listing, labeling, safety substantiation, and adverse-event reporting. The specific obligations depend on who you are in the supply chain (facility owner, Responsible Person, importer), whether a small-business exemption applies, and whether your product's claims or ingredients move it into drug territory. This guide walks through each requirement so you know which ones apply to your situation.

Key Takeaways

• Most cosmetics do not need FDA premarket approval. A product that makes drug claims or contains certain active ingredients may be regulated as a drug or as both a drug and a cosmetic.
• MoCRA created distinct obligations for facility owners/operators (registration) and Responsible Persons (product listing, adverse-event reporting, safety substantiation).
• Certain small businesses may qualify for exemptions from registration, listing, and future GMP requirements, but eligibility depends on statutory conditions and product categories.
• Registration and listing submissions through FDA Cosmetics Direct are free. Any charges from agents, consultants, or filing services are third-party fees.
• Ordinary cosmetics do not require FDA Prior Notice at import. FDA reviews cosmetic entries through its standard import process.

Liz Song is the founder of ALTA MEET, a sourcing consultancy that connects indie beauty founders with Korean ODM and OEM manufacturers. She coordinates between Korean production facilities and U.S. regulatory requirements.

Cosmetic versus Drug Classification

FDA classifies products based on their intended use, not where they are manufactured. A moisturizer sold to hydrate skin is a cosmetic. The same formula marketed to "treat eczema" or "reduce wrinkles" may be regulated as a drug, or as both a drug and a cosmetic, because those claims describe a therapeutic or structure/function effect.

This distinction matters because drugs face an entirely different regulatory pathway, including premarket approval or an applicable monograph. Common Korean skincare ingredients that can trigger drug classification include sunscreen actives (regulated under the OTC drug monograph), benzoyl peroxide for acne, and any ingredient paired with treatment claims on the label or marketing.

Color additives used in cosmetics generally require FDA approval for their intended use, regardless of the product's overall classification. If your product contains a colorant, confirm it is approved for use in cosmetics and for the specific application area (eyes, lips, general use).

Before importing, review every claim on your packaging, website, and marketing materials. A single treatment claim can shift the entire product into drug territory and change every compliance step that follows.

Roles in the MoCRA Framework

MoCRA assigns obligations to specific parties. Understanding which role you occupy determines which requirements fall on you.

Role	Who This Is	Key Obligations
Facility owner/operator	The Korean ODM/OEM that manufactures or processes the product	Register the facility (unless exempt); renew every two years from initial registration date
U.S. agent	A person or business located in the U.S. designated by the foreign facility	Serve as FDA's point of contact for the facility; this is separate from the Responsible Person role
Responsible Person	The manufacturer, packer, or distributor whose name appears on the product label	Product listing, annual listing updates, safety substantiation, serious adverse-event reporting, label contact info for adverse events
Importer / customs broker	The Importer of Record and their broker who handle U.S. entry	File entry with CBP, pay duties, respond to any FDA examination or document requests during import review

A common point of confusion: the U.S. agent and the Responsible Person are separate roles with different obligations. A U.S. agent is designated by the foreign facility for FDA communications about the facility. The Responsible Person is determined by whose name appears on the product label and handles product-level obligations. One entity can serve in both roles, but the roles themselves are distinct.

Facility Registration and Product Listing

These are two separate requirements under MoCRA, handled by different parties through different processes.

Facility registration is the responsibility of the facility owner or operator. If your Korean ODM manufactures or processes cosmetics for the U.S. market, the facility may need to be registered with FDA (unless an exemption applies). A foreign facility that is required to register must designate a U.S. agent.

Product listing is the responsibility of the Responsible Person. Each cosmetic product marketed in the U.S. must be listed with FDA, and listings must be updated annually. The Responsible Person also maintains safety substantiation documentation and handles serious adverse-event reporting.

Both registration and listing are submitted through FDA Cosmetics Direct, and both submissions are free. Registration and listing do not constitute FDA approval or certification of your products.

Renewal Dates and Annual Updates

Facility registration must be renewed every two years from the facility's initial registration date. There is no universal renewal deadline that applies to all facilities. Your renewal window depends on when your specific facility first registered.

Product listings must be updated annually. This includes updating listings when products are added, discontinued, or reformulated.

Track both dates. If you work with multiple Korean ODMs, each facility has its own registration renewal timeline.

Small-Business and Other Exemptions

MoCRA provides certain exemptions from facility registration, product listing, and future GMP requirements for qualifying small businesses. The statutory threshold is average gross annual U.S. cosmetic sales of $1,000,000 or less over the previous three-year period, adjusted for inflation.

Important qualifications:

• The exemption does not apply to products that contain certain categories of ingredients, such as those that are or have been subject to a drug application.
• Facility and Responsible Person eligibility must be considered separately. If you are a small indie brand but your Korean ODM is a large manufacturer, the ODM facility may not qualify for the facility registration exemption based on its own sales volume.
• Even exempt businesses must still comply with labeling requirements, adverse-event reporting for serious events, and the prohibition on adulterated or misbranded cosmetics.
• The inflation-adjusted dollar threshold may change. Check the FDA MoCRA page for the current figure before relying on any specific number.

FDA Fees versus Third-Party Service Fees

Submitting facility registration and product listings through Cosmetics Direct is free. FDA does not charge a registration fee or a listing fee for cosmetics.

Any fee you encounter for "FDA registration" or "MoCRA compliance filing" is a charge from a third-party service provider: a consultant, a regulatory agent, a law firm, or a software platform. These services can be helpful, especially for founders unfamiliar with the system, but the underlying FDA submissions carry no government fee.

When budgeting, distinguish between the cost of the regulatory work itself (free through FDA) and the cost of professional help you choose to hire. Get quotes from multiple providers and understand exactly what each service covers.

Labeling, Safety Substantiation, and Adverse-Event Reporting

Labeling is one of the most common reasons cosmetic shipments face issues at the border. U.S. cosmetic labeling requirements apply regardless of where the product is manufactured and include:

• Product identity and net quantity on the principal display panel
• Name and address of the manufacturer, packer, or distributor (this determines who the Responsible Person is)
• Ingredient list using INCI nomenclature, in descending order of predominance
• Required warnings where applicable
• Contact information for reporting adverse events (a MoCRA addition)

Korean packaging often needs modification for the U.S. market. Work with your ODM to incorporate English-language labeling that meets FDA requirements before production, not after shipment arrives.

Safety substantiation: The Responsible Person must maintain adequate substantiation of safety for each product. MoCRA does not prescribe a specific testing protocol, but the substantiation must be sufficient to support the product's safety under labeled or customary conditions of use.

Adverse-event reporting: The Responsible Person must submit serious adverse-event reports to FDA within 15 business days of receiving the report. Product labels must include domestic contact information for consumers to report adverse events. Maintain records of all adverse-event reports for at least six years.

FDA Import Entry Review

Cosmetics are reviewed by FDA at the customs entry stage; there is no separate prior notice filing for cosmetics. That requirement applies to food.

When cosmetics arrive at a U.S. port, FDA may review the entry as part of its standard import review process. This can include examining the product, reviewing labeling, and requesting documentation. Not every shipment is examined; FDA uses a risk-based approach to select entries for review.

If FDA identifies a problem, several actions are possible, and each has its own procedures and timelines:

• Import Alert: An internal FDA enforcement tool that flags products, firms, or countries for increased scrutiny. An Import Alert is not a notice sent to the importer; it is guidance to FDA field staff. Products on an Import Alert may be detained without physical examination.
• Detention and Notice of FDA Action: If FDA detains a shipment, the owner or consignee receives a Notice of FDA Action explaining the reason. The notice provides an opportunity to respond, but the applicable timeframe depends on the specific situation and the type of action.
• Refusal of admission: If the product is found to violate applicable law and the issues are not resolved, FDA can refuse admission.

Storage and demurrage costs during any hold period vary by port, warehouse, and shipment size. Get specifics from your freight forwarder or customs broker before your first shipment. Having your documentation organized, your labeling correct, and your facility registered (if required) reduces the risk of delays.

GMP and Fragrance-Allergen Rules Still Pending

MoCRA directs FDA to establish cosmetic Good Manufacturing Practice (GMP) regulations. As of this review, the FDA page for cosmetic GMP still identifies this as rulemaking work in progress. No final GMP rule has been published, and no compliance date has been announced. Brands should follow existing ISO 22716 cosmetic GMP guidelines as a best practice and monitor FDA rulemaking for updates.

Similarly, MoCRA directs FDA to establish fragrance-allergen labeling requirements. This rulemaking is also still in progress. No final U.S. rule requires disclosure of specific fragrance allergens at this time. The EU already requires disclosure of certain fragrance allergens on cosmetic labels, and some brands voluntarily align with EU requirements in anticipation of future U.S. rules, but this is not currently required by U.S. law.

Monitor the FDA MoCRA page for both rulemakings. When these rules are finalized, compliance timelines will be specified.

Pre-Launch Checklist

Before Production

• Confirm product classification: cosmetic only, drug, or both. Review all claims and active ingredients.
• Verify whether the Korean manufacturing facility needs FDA registration. If required, confirm it is registered and the U.S. agent is designated.
• Identify the Responsible Person (whose name will appear on the label).
• Check whether a small-business exemption applies to the facility and/or the Responsible Person, considering the product-category exclusions.

Before Printing Packaging

• Review final label artwork against FDA cosmetic labeling requirements: identity, net quantity, ingredient list (INCI, descending order), name and address, warnings, adverse-event contact information.
• Verify all color additives are FDA-approved for the intended use area.
• Confirm no unsubstantiated drug claims appear on packaging or inserts.

Before Shipping

• List products on Cosmetics Direct (free) if the Responsible Person is required to do so.
• Set up adverse-event tracking and recordkeeping systems.
• Maintain safety substantiation documentation.
• Coordinate with your customs broker on entry documentation and HTS classification.

After Launch

• Monitor and report serious adverse events within 15 business days.
• Update product listings annually and when products change.
• Track the facility registration renewal date (every two years from initial registration).
• Monitor FDA rulemaking for GMP and fragrance-allergen requirements.

Frequently Asked Questions

Does FDA registration cost anything?

Submitting facility registration and product listings through Cosmetics Direct is free. Any fee you pay is for a third-party service (consultant, agent, software), not an FDA fee.

Is registration the same as FDA approval?

No. FDA registration and product listing are notification and transparency requirements. They do not constitute FDA approval, certification, or endorsement of any product. FDA does not approve cosmetics before they go to market (with the exception of color additives, which require approval).

Are trade-show samples or R&D samples exempt from MoCRA?

Treatment of samples depends on their intended use, whether they enter commercial distribution, the specific facts of the entry, and applicable law. Do not assume any category of sample is automatically exempt. Consult a regulatory professional or customs broker for your specific situation.

My Korean ODM says they are already FDA-registered. Do I still need to do anything?

Yes. Facility registration is the ODM's obligation as the facility owner/operator. You likely have separate obligations as the Responsible Person (the party whose name appears on the label), including product listing, adverse-event reporting, safety substantiation, and labeling compliance.

When do I need to renew facility registration?

Every two years from the facility's initial registration date. There is no single universal renewal deadline. Check with your ODM or your U.S. agent to confirm the specific renewal window for each facility you work with.

Official Sources

• FDA: Registration and Listing of Cosmetic Product Facilities and Products
• FDA: Modernization of Cosmetics Regulation Act of 2022 (MoCRA)
• FDA: Importing Cosmetics
• FDA: Entry Review
• FDA: Prior Notice of Imported Foods (included to clarify this does not apply to cosmetics)
• 21 U.S.C. § 364h – Small-business exemptions

Navigating Korean manufacturing contracts and U.S. regulatory coordination can be complicated, especially for first-time importers.

Book a free 15-minute introductory call to discuss your Korean manufacturing and regulatory-coordination needs.